drugset / Trial / NCT02614872

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

NCT02614872

Phase 2 Completed 30 enrolled Kamada, Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the safety and efficacy of intravenous GLASSIA® treatment in lung transplantation.

Timeline

Start
2016-07-26
Primary completion
2019-04-11
Completion
2019-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Alpha 1-Antitrypsin Protein / enzyme biologic Intravenous

Indications